Evidence map›Paper›PMID 42328451›Full record

ArticleInternational journal of biological sciences2026

Targeting SRSF6 to Enhance Cisplatin Sensitivity by Modulating Redox Balance via NFE2L1 exon 4 Splicing in ESCC.

Xinyu He, Jialuo Xu, Lina Duan, Jing Ma, Dan Gao, Yifei Xie, Dengyun Zhao, Jialin Liu, Jimin Zhao, Fangfang Liu and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Xinyu HeState Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer; School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450000, Henan, China.
Jialuo XuState Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer; School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450000, Henan, China.
Lina DuanState Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer; School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450000, Henan, China.
Jing MaChina-US (Henan) Hormel Cancer Institute, Zhengzhou 450000, Henan, China.
Dan GaoChina-US (Henan) Hormel Cancer Institute, Zhengzhou 450000, Henan, China.
Yifei XieState Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer; School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450000, Henan, China.
Dengyun ZhaoState Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer; School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450000, Henan, China.
Jialin LiuState Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer; School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450000, Henan, China.
Jimin ZhaoState Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer; School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450000, Henan, China.
Fangfang LiuState Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer; School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450000, Henan, China.
Mee-Hyun LeeCollege of Korean Medicine, Dongshin University, Naju, Republic of Korea.
Myoung Ok KimDepartment of Animal Science and Biotechnology, Kyungpook National University, Sangju, Republic of Korea.
Zigang DongState Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer; School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450000, Henan, China.
Yanan JiangState Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer; School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450000, Henan, China.
Kangdong LiuState Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer; School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450000, Henan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mechanisms by which cancer cells survive and adapt under high levels of reactive oxygen species (ROS) remain poorly understood, especially in the context of redox homeostasis. This study reveals increased oxidative stress in esophageal squamous cell carcinoma (ESCC), with serine/arginine-rich splicing factor 6 (SRSF6) playing a crucial role in maintaining redox homeostasis. SRSF6 binds to the exonic splicing enhancer (ESE) motif in nuclear factor erythroid 2-related factor 1 (NFE2L1

Indexed as

CisplatinEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaNF-E2-Related Factor 1Serine-Arginine Splicing FactorsApoptosisCell Line, TumorCell ProliferationExonsHumansOxidation-ReductionOxidative StressPhosphoproteinsReactive Oxygen SpeciesCisplatinNFE2L1 protein, humanNF-E2-Related Factor 1PhosphoproteinsReactive Oxygen SpeciesSerine-Arginine Splicing FactorsSRSF6 protein, humanalternative splicingantisense oligonucleotidescisplatinNFE2L1SRSF6

Identifiers

PMID42328451
PMCPMC13282889

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.